MYO-029

Small molecule

Pfizer

MYO-029 is one of 19 small molecule programs targeting Muscular Dystrophy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscular DystrophyActive, not recruiting

Muscular DystrophyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Muscular Dystrophy

#DrugCompanyPhaseTrials

Cialis

Glucophage

Duvyzat

1 4

Glucocorticoid

AbbVie

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 2

1 6

Emflaza

PPTC Therapeutics

Phase 3

1 7

Translarna

PPTC Therapeutics

Phase 2

—8

Bisphosphonate Treatment

UUniversité Catholique de Louvain

Approved

1 9

Stem Cell

NNeurogen Brain and Spine Institute

Phase 2

3 10

Trehalose

SSeelos Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Muscular Dystrophy1 trial

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00104078·108 enrolled

Tics1 trial

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Completed· Pfizer logo

Pfizer·Phase 1·NCT00563810·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MYO-029. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MYO-029 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MYO-029. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Pfizer

MYO-029

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Muscular Dystrophy1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News